Emerging PDE4 Inhibitors for Psoriasis and Inflammatory Disorders

Phosphodiesterase-4 (PDE4) enzymes represent a class of cAMP-specific phosphodiesterases that are responsible for regulating intracellular cAMP levels in immune and inflammatory cells of the type monocyte, macrophage, dendritic cell, neutrophil, and T lymphocyte [1]. By the process of hydrolyzing cAMP to the inactive 5′-AMP, PDE4s end the cAMP-dependent signaling, thus they are the main promoters of pro-inflammatory cascades [1]. Normally, cAMP inhibits cytokines like TNF-α, IL-17, and IFN-γ, at the same time it promotes anti-inflammatory IL-10. In psoriasis, however, deregulated cAMP signaling results in keratinocyte hyperproliferation and sustained inflammation [2]. The inhibition of PDE4 returns cAMP levels to normal, initiates PKA, and blocks NF-κB and MAPK pathways, which is followed by less cytokine release and immune activation [3]. First PDE4 inhibitors such as rolipram were effective but accompanied by systemic side effects, mostly nausea and vomiting due to nonselective PDE4D inhibition [4]. Nevertheless, changes from 2022 to 2025 led to the development of safe, targeted drugs such as topical roflumilast and crisaborole that reduce systemic exposure [5]. New generations comprise also isoform-selective (PDE4B/D) inhibitors, bifunctional molecules, and PROTAC degraders that improve both the effectiveness and the patient's comfort [5]. The inventions have contributed to the positioning of PDE4 inhibitors as potential biologics' viable substitutes, thus enabling the patients to have both localized and systemic anti- inflammatory therapy at a lower price and with less inconvenience [6]. In inflammatory skin disorders such as psoriasis and its comorbidities, the blockade of PDE4 leads to the normalization of immune signaling, keratinocyte function, and inflammation, thus representing a significant breakthrough in precision anti-inflammatory therapy [7].

Table I: Table of Demographic Data

2. Causes of Psoriasis and Related Inflammatory Disorders:

2.1 Genetic Susceptibility:

Psoriasis is primarily a genetically based condition with its genes spread over several loci like PSORS1 on chromosome 6p21 that produces HLA-Cw6 — a major histocompatibility antigen involved in antigen presentation to T-cells [1]. Research evidences that the risk in first-degree relatives is increased by 4–6 times, thus confirming the hereditary nature of the disease [2]. Besides that, genetic variations that influence PDE4B and PDE4D mRNA levels have been associated with sever inflammatory responses [3].

2.2 Immune System Dysregulation:

The main cause of psoriatic inflammation is the rise in IL-17, IL-23, and TNF-α production due to the excessive stimulation of dendritic cells (DCs) and T-helper (Th1, Th17) subpopulations [4]. The immune cells undergoing the overactivated cAMP–PDE4 pathway have very low intracellular cAMP levels, which leads to increased cytokine secretion [5]. PDE4 inhibitors such as apremilast and roflumilast rectify the disturbed immune system by elevating cAMP and limiting cytokine release [6].

2.3 Environmental Triggers:

Besides a great number of other factors, an infectious disease (Streptococcus pyogenes), injury (Koebner phenomenon), stress, and smoking have been proven to worsen the condition of a psoriasis patient [7]. The sun rays and cold places may help to regulate the immune system thus aiding the patient’s condition [8]. Furthermore, the division of PDE4 in keratinocytes markedly increases due to exposure to peroxide and bacteria thus leading to aggravation of inflammation [9].

2.4 Neuroendocrine and Stress Axis Dysregulation:

Oftentimes stress results in activation of the hypothalamic–pituitary–adrenal (HPA) axis which, by elevating catecholamine and cortisol levels, ultimately leads to increased production of inflammatory mediators in psoriatic lesions [10]. The loop of interaction between cortisol feedback and release of proinflammatory cytokines that leads to skin inflammation. PDE4 inhibitors are capable of restoring the balance by returning cAMP to its role in neuroimmune signaling [11].

2.5 Metabolic and Oxidative Stress:

Psoriasis goes hand in hand with health disorders like metabolic syndrome, obesity, and insulin resistance that pave the way to systemic inflammation through elevating IL-6, CRP, and TNF-α levels [12]. Besides that, oxidative damage to skin cells and enhancement of PDE4 enzymes lead to more intensive cytokine signaling [13]. Employing PDE4 as a target can help in lessening oxidative-induced inflammatory processes [14].

2.6 Drug- and Chemical-Induced Factors:

Drugs such as β-blockers, lithium, antimalarials, and NSAIDs are capable of not only inducing but also aggravating psoriatic lesions [15]. These substances interfere with the cyclic nucleotide levels and immune regulation procedures. PDE4 blockade ameliorates the intracellular communication that is disturbed by these drugs [16].

3. Pathophysiology of Psoriasis and PDE4-Targeted Inflammatory Diseases:

Figure I: Pathophysiology of Psoriasis

3.1 cAMP–PDE4 Signaling Axis:

The principal enzyme responsible for the degradation of cAMP is phosphodiesterase-4 (PDE4) in immune and skin cells [17]. The reduced cAMP caused by the overexpression of PDE4 results in the activation of NF-κB and AP-1, transcription factors that are involved in the production of TNF-α, IL-17, and IL-23 [18]. The inhibition of PDE4 brings back cAMP levels, thus preventing these proinflammatory transcriptional cascades [19].

3.2 Keratinocyte Hyperproliferation and Differentiation Defect:

Keratinocytes in psoriatic plaques show replication activity that is significantly faster (4–7 days vs. 28 days in normal skin) [20]. The excessively active PDE4B/D in keratinocytes leads to cAMP decrease and thus keratinocytes overgrowth is achieved via ERK/MAPK signaling [21]. A topical PDE4 inhibitor like roflumilast 0.3% not only normalizes epidermal proliferation but also improves the barrier function of the skin [22].

3.3 Immune Cell Activation and Cytokine Cascade:

IL-12 and IL-23 are the cytokines that dendritic cells produce upon their activation. These cytokines stimulate the Th1 and Th17 responses. As a result of the activation, these T-cells secrete IFN-γ, IL-17, IL-22, and thus the inflammation becomes chronic [23]. The use of PDE4 inhibitors leads to a decrease in the production of these cytokines and at the same time, an anti- inflammatory cytokine - IL-10 is increased [24].

3.4 Neutrophil and Monocyte Infiltration:

The increase in PDE4 expression results in the intensification of neutrophil chemotaxis and macrophage activation, which in turn leads to the release of myeloperoxidase and reactive oxygen species [25]. After the blockade of PDE4, a decrease in the expression of the adhesion molecules (ICAM-1, VCAM-1) occurs which thus limits leukocyte infiltration [26].

3.5 Vascular and Angiogenic Changes:

Psoriatic lesions are characterized by increased VEGF expression and angiogenesis in dermal papillae [27]. By inhibiting PDE4, VEGF transcription is blocked due to the stabilization of intracellular cAMP, thus resulting in less vascular proliferation [28].

3.6 PDE4 in Other Inflammatory Diseases:

In addition to psoriasis, PDE4 is also involved in the pathogenesis of atopic dermatitis, COPD, and psoriatic arthritis. Both topical and systemic PDE4 inhibitors (e.g., apremilast, roflumilast, ME3183) have been reported to exert significant anti-inflammatory effects in skin-, joint-, and airway-related conditions. The new generation drugs like ME3183 and PDE4 degraders have greater binding affinity to PDE4B/D leading to fewer side effects related to emesis [29], [30], [31].

4. Signs and Symptoms of Psoriasis:

Psoriasis is an immunologically-mediated chronic inflammatory disorder of the skin; however, it can extend to the nails, joints, and other organs. A hallmark of the disease is the immune dysregulation characterized by the involvement of T-cells, dendritic cells, and cytokines such as TNF-α, IL-17, IL-23, and IFN-γ — inflammatory mediators, which are also modulated by PDE4 enzyme activity [1], [2]. The clinical features are the result of keratinocytes hyperproliferation and defective terminal differentiation co-occurring with chronic inflammatory infiltrate in both dermis and epidermis

Figure II: Signs and Symptoms of Psoriasis

4.1. Cutaneous Manifestations:

The hallmark presentation of psoriasis is the appearance of well-demarcated, erythematous (red), scaly plaques that vary in size and distribution.

• Plaque formation: The lesions are sharply bordered and covered with silvery-white scales, resulting from rapid turnover of epidermal keratinocytes (as the normal 28-day cycle is shortened to 3–5 days) [2].

• Auspitz Sign: When these scales are gently removed, pinpoint bleeding occurs due to the exposure of dilated dermal capillaries beneath the thinned suprapapillary epidermis — a classic diagnostic feature known as the Auspitz sign [2].

• Koebner Phenomenon: Psoriatic lesions may appear at sites of trauma or irritation, a response termed the Koebner phenomenon, which reflects immune activation and cytokine release at sites of skin injury [2].

• Itching and burning: Although not universal, many patients report pruritus, burning, or pain in affected areas due to inflammatory mediators such as TNF-α and IL-17 stimulating sensory nerve endings [3].

4.2. Nail Involvement (Nail Psoriasis):

Nail changes are common and may precede or accompany cutaneous symptoms.

• Pitting: The most characteristic sign, resulting from focal loss of keratin cells in the nail plate [3].

• Onycholysis: Separation of the nail from the nail bed, often with yellow discoloration beneath the nail [3].

• Subungual hyperkeratosis: Thickening under the nail plate due to excessive keratin deposition [3].

• Oil-drop (Salmon patch) sign: Yellow-brown discoloration visible through the nail plate, representing psoriatic inflammation of the nail bed [3]. Nail psoriasis is closely associated with psoriatic arthritis, indicating deeper systemic involvement [4].

4.3. Scalp Psoriasis:

The scalp is one of the most frequently affected areas, with thick, adherent scales extending beyond the hairline and accompanied by itching or pain [2]. Despite heavy scaling, hair loss is uncommon, distinguishing it from seborrheic dermatitis. Chronic scalp involvement often leads to social distress and significant psychosocial burden [4].

4.4. Psoriatic Arthritis (PsA):

Approximately 20–30% of psoriasis patients develop psoriatic arthritis, an inflammatory arthropathy that may precede or follow skin lesions [4].

• Joint pain, stiffness, and swelling are characteristic, often involving distal interphalangeal joints, sacroiliac joints, or the spine.

• Dactylitis (sausage digits): Diffuse swelling of entire fingers or toes due to inflammation of joints and tendons [4].

• Enthesitis: Inflammation at tendon or ligament insertion sites, commonly at the Achilles tendon or plantar fascia [4]. If untreated, chronic PsA can cause joint deformity and functional impairment due to erosive damage and persistent inflammation [4].

4.5. Variants and Subtypes of Psoriasis:

• Several morphological variants exist, each with distinct clinical and pathological profiles [2],[3].

• Plaque Psoriasis (Psoriasis Vulgaris): The most common form, accounting for ~80–90% of cases. Characterised by stable plaques with silvery scales and symmetrical distribution.

• Guttate Psoriasis: Sudden onset of small, drop-like lesions often triggered by streptococcal throat infections in younger individuals.

• Inverse (Flexural) Psoriasis: Found in intertriginous areas (axillae, groin, under breasts); lesions are shiny, red, and lack scaling due to moisture.

• Pustular Psoriasis: Characterised by sterile pustules filled with neutrophils on erythematous skin; may be localized (palmar/plantar) or generalized.

• Erythrodermic Psoriasis: A severe, potentially life-threatening form involving diffuse erythema, scaling, fever, and systemic illness; often precipitated by abrupt withdrawal of corticosteroids or systemic triggers. Each variant reflects differing degrees of immune activation and cytokine dominance, aligning with the PDE4-cAMP regulatory imbalance seen in psoriasis pathophysiology [1],[3].

4.6. Systemic and Psychosocial Symptoms:

Beyond visible lesions, psoriasis exerts a profound systemic and psychological impact.

• Systemic inflammation:

Chronic cytokine release contributes to comorbidities such as metabolic syndrome, obesity, hypertension, and cardiovascular disease [4].

• Fatigue and malaise are common due to inflammatory cytokines such as TNF-α and IL-6 affecting energy metabolism [4].

• Psychological distress:

Patients often experience anxiety, depression, social withdrawal, and reduced quality of life due to the visible and stigmatizing nature of the disease [4]. These psychosomatic consequences underline the need for therapies like PDE4 inhibitors, which not only suppress inflammation but also improve patient well-being through better symptom control [5], [6], [7].

5. Mechanism of PDE4 Inhibition in Inflammatory Pathways:

hosphodiesterase-4 (PDE4) enzymes are primary controllers of the intracellular second messenger cyclic adenosine monophosphate (cAMP). In immune and inflammatory cells, cAMP is a repressor of pro-inflammatory cytokine production through the activation of protein kinase A (PKA), exchange protein activated by cAMP (Epac), and downstream transcriptional regulators like CREB (cAMP-response element-binding protein) [11]. PDE4 is the enzyme that performs the deactivation of cAMP to 5′-AMP, thus ending the anti-inflammatory signal. The blockade of PDE4 results in a continuous rise of intracellular cAMP, which causes the inhibition of TNF-α, IL-2, IL-12, IL-17, IL-23, and the promotion of anti-inflammatory cytokines such as IL-10 [12]. Such a process at the cellular level means less activation of T-cells, dendritic cells, macrophages, and keratinocytes, and therefore the psoriatic inflammation is reduced. Moreover, PDE4 inhibition is capable of both regulating epidermal proliferation and bringing back the skin barrier through intervention in oxidative stress and cytokine-driven hyperkeratosis [13].

Figure III: Mechanism of Pde4 Inhibition in Inflammatory Pathways

6. Classification and Isoform Distribution of PDE4:

PDE4 is a member of the PDE superfamily that contains 11 gene families (PDE1–PDE11) with each family having multiple isoforms. PDE4 itself has four main subtypes: PDE4A, PDE4B, PDE4C, and PDE4D besides that it has more than 25 splice variants. Every isoform exhibits different expression patterns in the various tissues, which greatly affects both the efficacy and the side effects [15]. Selective isoform blockade (especially PDE4B > PDE4D) is a cutting-edge approach to eliminate nausea while keeping the positive effect intact [16]. A point of partial PDE4B selectivity exists in apremilast and roflumilast while the advanced scaffold (such as ME3183, LYF-36) is made for isoform fine-tuning [17]

Table II: Pde4 Isoforms, Tissue Distribution, And Functional Roles

6.1 Structure–Activity Relationship (SAR) of PDE4 Inhibitors:

SAR analyses have been the major factor in the innovation of new PDE4 inhibitors that have an ideal balance of potency, selectivity, and tolerability. The earliest pharmacophore model comprises a catechol-ether group that is connected to a pyridine, quinoline, or benzamide core [18].

Figure IV: Sar Of PDE4 Inhibitors

Table III: Compounds of Pde4 And Their Structure

6.2. Key SAR Principles:

• Hydrophobic Interactions: The substitution of the benzamide ring improves hydrophobic binding in the PDE4 catalytic pocket, thereby increasing the activity of the compound (this has been shown in the analogues of apremilast and roflumilast) [19].

• Hydrogen Bond Donors/Acceptors: Donor groups (e.g., –OH, –NH?) present facilitate the interaction with the conserved glutamine residue (Gln369) that is essential for the catalytic inhibition [20].

• Rigidification of Scaffolds: Conformationally limited molecules (such as difamilast) are less likely to bind non-target sites, thus their tolerability is better [21].

• Topical Optimisation: By increasing lipophilicity and at the same time restricting systemic penetration, dermal retention is improved and GI side effects are reduced (e.g., roflumilast cream, crisaborole) [22]